- Spark Newswire

1 minute read

Cingulate Concludes Enrollment In Early Stage Anxiety Trial

Today, 2:15 PM

Cingulate Inc. (NASDAQ: CING) has completed enrollment in its study to determine the appropriate formulation of its third asset, CTx-2103, for the management of anxiety-related disorders. The early stage study has enrolled 12 patients after the initiation early this month.

CING

1 minute read

Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study

By Ragothaman Srinivasan

Today, 2:15 PM

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).

AERI

1 minute read

FDA Approves Regeneron and Sanofi’s Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

By Ragothaman Srinivasan

Today, 2:15 PM

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

REGN

1 minute read

Aileron Treats First Patient With ALRN-6924 In Breast Cancer Setting

By Ragothaman Srinivasan

Today, 2:15 PM

Aileron Therapeutics (NASDAQ: ALRN) enrolled the first patients in its Phase 1b clinical trial evaluating ALRN-6924 for bone marrow in patients patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D).

ALRN

1 minute read

Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug

By Ragothaman Srinivasan

Today, 2:15 PM

Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The company is planning to start a clinical study evaluating XMT-2056 for gastric and other cancers.

MRSN

1 minute read

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint

By Ragothaman Srinivasan

Today, 2:15 PM

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial Virus (RSV).

ENTA

1 minute read

IO Biotech Starts Dosing In Late-Stage IO102-IO103/Keytruda Combo Trial In Melanoma Patients

By Ragothaman Srinivasan

Today, 2:15 PM

IO Biotech (NASDAQ: IOBT) dosed first patient in its phase 3 clinical trial of lead drug candidate, IO102-IO103, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with previously untreated, unresectable or metastatic (advanced) melanoma.

IOBT

1 minute read

Sorrento Therapeutics shares are trading high following FDA clearance of IND for Abivertinib in metastatic castrate resistant prostate cancer (mCRPC)

By Ragothaman Srinivasan

Today, 2:15 PM

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug application (IND) of Abivertinib (Fujovee) for patients with metastatic castrate resistant prostate cancer (mCRPC) in the Phase 2 MAVERICK clinical study.

SRNE

1 minute read

C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers

By Ragothaman Srinivasan

Today, 2:15 PM

C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors.

CCCC

1 minute read

scPharmaceuticals Shares Are Trading High Following FDA’s Acceptance of NDA for FUROSCIX

By Ragothaman Srinivasan

Today, 2:15 PM

scPharmaceuticals Inc. (NASDAQ: SCPH) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of the drug candidate FUROSCIX, for the treatment of congestion in patients with worsening heart failure.

SCPH